Gene therapy, biotechnology, and clinical research by Solid Biosciences
European Commission grants Orphan status to Solid Biosciences SGT-212 as fifth patient dosed
Solid Biosciences has been granted Orphan designation by the European Commission for SGT-212, its investigational gene therapy targeting Friedreich’s ataxia. The company also announced that ...
Solid Biosciences to present seven posters on Duchenne and platform advances at ESGCT2026
Solid Biosciences will deliver seven presentations at ESGCT2026, covering updates on its Duchenne program and platform technologies including POLARIS-101, its next-generation engineered myotropic ...
Solid Biosciences unveils POLARIS-101 next-generation capsid for gene therapy delivery
Solid Biosciences has introduced POLARIS-101, a proprietary next-generation muscle-tropic capsid designed to enhance safe, efficient, and scalable delivery of genetic medicines across ...
New data from Solid Biosciences to be shared at neuromuscular research event
Solid Biosciences announced it will participate in the Annual Neuromuscular Study Group Scientific Meeting, presenting two posters focused on Duchenne muscular dystrophy. The company will share ...
Solid Biosciences Inc. brings patient advocates to FA panel at GMP Lab
Solid Biosciences Inc. recently convened with patient advocates at a panel hosted at PPDCRO's GMP Lab in Middleton, Wisconsin. The meeting focused on direct experiences of those impacted by ...
Financial results and business update issued by Solid Biosciences for second quarter 2026
Solid Biosciences released its financial results for the second quarter of 2026, highlighting key updates in its business operations and development pipeline. The announcement provides insights ...
Solid Biosciences Inc. joins FARA Boston ride to support Friedreich ataxia research
Solid Biosciences Inc. participated in the fourth annual rideATAXIA Hometown Boston bike ride, an event organized by the Friedreich's Ataxia Research Alliance (FARA) to promote research and ...
Solid Biosciences Inc. connects with patients and stakeholders at 2026 annual Duchenne event
Solid Biosciences Inc. participated in the 2026 ParentProjectMD Annual Conference, expressing gratitude for the opportunity to engage directly with patients, families, advocates, clinicians, and ...
Solid Biosciences Inc. joins BAA 10K to fund cancer research advancement
Solid Biosciences Inc. participated in the Boston Athletic Association's 10K race, sponsored by Mass General Brigham Cancer Institute, to raise funds for cancer research and patient care. The ...
Solid Biosciences Inc. joins Parent Project Muscular Dystrophy event to connect Duchenne community
Solid Biosciences Inc. announced its participation as an attendee, sponsor, and exhibitor at the Parent Project Muscular Dystrophy 2026 Annual Conference, which will be held in Orlando from June ...
Solid Biosciences Inc. targets platform partnerships at BIO2026 in San Diego
Solid Biosciences Inc. is preparing to engage with industry peers and potential partners at the upcoming BIO2026 conference in San Diego. The company is encouraging participants in the genetic ...
Solid Biosciences Inc. targets industry collaboration ahead of BIO2026 to accelerate genetic medicine
Solid Biosciences Inc. is gearing up for BIO2026, aiming to connect with key industry leaders and innovators in the field of precision genetic medicine. The company is inviting those interested ...
Solid Biosciences Inc. partners with Jett Foundation for 25th Anniversary Silver Soirée sponsorship
Solid Biosciences Inc. has announced its sponsorship of the Jett Foundation's 25th Anniversary Silver Soirée, set for June 11. The company expressed its continued commitment as a longstanding ...
NanoMosaic alliance positions Solid Biosciences Inc. to advance precision AAV capsid research
Solid Biosciences Inc. has entered into a co-marketing agreement with NanoMosaic, aiming to drive forward the development of next generation gene therapies. The partnership focuses on unlocking ...
Solid Biosciences joins Jefferies Global Healthcare Conference with CEO Bo Cumbo fireside chat
Solid Biosciences will participate in the Jefferies Global Healthcare Conference on June 3, where President and CEO Bo Cumbo is scheduled for a fireside chat at 7:35 AM ET. The company announced ...
Solid Biosciences Inc. spotlights Patrick González SGT-003 insights at major DMD conference
Solid Biosciences Inc. presented its next-generation gene therapy candidate, SGT-003, for Duchenne muscular dystrophy (DMD) during a high-profile Clinical Trials session last week. Patrick ...
Solid Biosciences Inc. to host webinar on SGT-003 gene therapy for Duchenne
Solid Biosciences Inc. announced it will co-host a free community webinar with Defeat Duchenne on Wednesday, May 27, at 1:00 PM ET. The event will cover SGT-003, Solid Biosciences Inc.'s ...
Solid Biosciences Chief Medical Officer presents targeted therapy delivery approach at Boston biotech conference
Solid Biosciences announced that Chief Medical Officer Gabriel Brooks, M.D., will present at FierceBiotechWeek in Boston on Wednesday, May 13. Brooks will address one of genetic medicine’s ...
